Publication Information (EuropePMC) | |
Title | Genetically adjusted PSA levels for prostate cancer screening. |
PubMed ID | 37264206(Europe PMC) |
doi | 10.1038/s41591-023-02277-9 |
Publication Date | June 1, 2023 |
Journal | Nat Med |
Author(s) | Kachuri L, Hoffmann TJ, Jiang Y, Berndt SI, Shelley JP, Schaffer KR, Machiela MJ, Freedman ND, Huang WY, Li SA, Easterlin R, Goodman PJ, Till C, Thompson I, Lilja H, Van Den Eeden SK, Chanock SJ, Haiman CA, Conti DV, Klein RJ, Mosley JD, Graff RE, Witte JS. |
Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS003379 (PSA_PGS_CSx) |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Prostate-specific antigen (PSA) levels | prostate specific antigen amount | 1,071,278 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003379/ScoringFiles/PGS003379.txt.gz |
PGS003378 (PSA_PGS_128) |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Prostate-specific antigen (PSA) levels | prostate specific antigen amount | 128 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003378/ScoringFiles/PGS003378.txt.gz |
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM016240 | PGS003378 (PSA_PGS_128) |
PSS010066| European Ancestry| 5,725 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.169 | — | Partial R2 (%, variation explained by the PGS only): 7.33 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016241 | PGS003378 (PSA_PGS_128) |
PSS010073| Multi-ancestry (including European)| 25,917 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.207 | — | Partial R2 (%, variation explained by the PGS only): 8.0 | Age at PSA measurement, population-specific genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016242 | PGS003378 (PSA_PGS_128) |
PSS010072| European Ancestry| 22,173 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.213 | — | Partial R2 (%, variation explained by the PGS only): 8.78 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016243 | PGS003378 (PSA_PGS_128) |
PSS010070| African Ancestry| 2,936 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.154 | — | Partial R2 (%, variation explained by the PGS only): 3.36 | Age at PSA measurement, population-specific genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016244 | PGS003378 (PSA_PGS_128) |
PSS010068| African Ancestry| 1,173 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.163 | — | Partial R2 (%, variation explained by the PGS only): 3.45 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016245 | PGS003378 (PSA_PGS_128) |
PSS010069| African Ancestry| 1,763 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.146 | — | Partial R2 (%, variation explained by the PGS only): 3.32 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016246 | PGS003378 (PSA_PGS_128) |
PSS010071| East Asian Ancestry| 257 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.136 | — | Partial R2 (%, variation explained by the PGS only): 2.45 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016248 | PGS003379 (PSA_PGS_CSx) |
PSS010066| European Ancestry| 5,725 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.194 | — | Partial R2 (%, variation explained by the PGS only): 8.6 | Age at PSA measurement, within-population genetic ancestry PC1-PC10 | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,058,173 SNPs) |
PPM016249 | PGS003379 (PSA_PGS_CSx) |
PSS010073| Multi-ancestry (including European)| 25,917 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.258 | — | Partial R2 (%, variation explained by the PGS only): 9.61 | Age at PSA measurement, within-population genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,071,278 SNPs) |
PPM016250 | PGS003379 (PSA_PGS_CSx) |
PSS010072| European Ancestry| 22,173 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.283 | — | Partial R2 (%, variation explained by the PGS only): 10.94 | Age at PSA measurement, within-population genetic ancestry PC1-PC10 | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,071,278 SNPs) |
PPM016251 | PGS003379 (PSA_PGS_CSx) |
PSS010070| African Ancestry| 2,936 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.134 | — | Partial R2 (%, variation explained by the PGS only): 3.11 | Age at PSA measurement, within-population genetic ancestry PC1-PC10, genetic ancestry proportions (AFR) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,071,278 SNPs) |
PPM016252 | PGS003379 (PSA_PGS_CSx) |
PSS010068| African Ancestry| 1,173 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.098 | — | Partial R2 (%, variation explained by the PGS only): 1.64 | Age at PSA measurement, within-population genetic ancestry PC1-PC10 | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,071,278 SNPs) |
PPM016239 | PGS003378 (PSA_PGS_128) |
PSS010067| Multi-ancestry (including European)| 5,883 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.168 | — | Partial R2 (%, variation explained by the PGS only): 7.16 | Age at PSA measurement, population-specific genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016247 | PGS003379 (PSA_PGS_CSx) |
PSS010067| Multi-ancestry (including European)| 5,883 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.186 | — | Partial R2 (%, variation explained by the PGS only): 8.13 | Age at PSA measurement, within-population genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,058,173 SNPs) |
PPM016253 | PGS003379 (PSA_PGS_CSx) |
PSS010069| African Ancestry| 1,763 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.157 | — | Partial R2 (%, variation explained by the PGS only): 4.22 | Age at PSA measurement, within-population genetic ancestry PC1-PC10 | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,071,278 SNPs) |
PPM016254 | PGS003379 (PSA_PGS_CSx) |
PSS010071| East Asian Ancestry| 257 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.258 | — | Partial R2 (%, variation explained by the PGS only): 9.22 | Age at PSA measurement, within-population genetic ancestry PC1-PC10 | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,071,278 SNPs) |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS010066 | Baseline/pre-randomization PSA in men without prostate cancer | — | 5,725 individuals, 100.0 % Male samples |
— | European (Predominantly European) |
European (EUR) ancestry cluster based on SNPWEIGHTS score >=0.80; median EUR = 0.998; mean EUR = 0.991 | PCPT | Minimum enrollment age was 55 years with serum PSA <= 3 ng/mL |
PSS010067 | Baseline/pre-randomization PSA in men without prostate cancer | — | 5,883 individuals, 100.0 % Male samples |
— | European, Not reported | Multi-ancestry pooled sample | PCPT | Minimum enrollment age was 55 years with serum PSA <= 3 ng/mL |
PSS010068 | Baseline/pre-randomization PSA in men without prostate cancer | — | 1,173 individuals, 100.0 % Male samples |
— | African American or Afro-Caribbean (Predominantly West African) |
West African (AFR) ancestry cluster based on SNPWEIGHTS score >=0.80; median AFR = 0.855; mean AFR = 0.861 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010069 | Baseline/pre-randomization PSA in men without prostate cancer | — | 1,763 individuals, 100.0 % Male samples |
— | African American or Afro-Caribbean (West African admixed) |
0.20 < West African (AFR) ancestry score <0.80 based on SNPWEIGHTS; median AFR = 0.673; mean AFR = 0.602 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010070 | Baseline/pre-randomization PSA in men without prostate cancer | — | 2,936 individuals, 100.0 % Male samples |
— | African American or Afro-Caribbean (West African admixed) |
West African (AFR) ancestry score >0.20 based on SNPWEIGHTS; median AFR = 0.765; mean AFR = 0.705 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010071 | Baseline/pre-randomization PSA in men without prostate cancer | — | 257 individuals, 100.0 % Male samples |
— | East Asian (Predominantly East Asian) |
East Asian (EAS) ancestry cluster based on SNPWEIGHTS score >=0.80; median EAS = 0.978; mean EAS = 0.972 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010072 | Baseline/pre-randomization PSA in men without prostate cancer | — | 22,173 individuals, 100.0 % Male samples |
— | European (Predominantly European) |
European (EUR) ancestry cluster based on SNPWEIGHTS score >=0.80; median EUR = 0.995; mean EUR = 0.986 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010073 | Baseline/pre-randomization PSA in men without prostate cancer | — | 25,917 individuals, 100.0 % Male samples |
— | European, African American or Afro-Caribbean | Multi-ancestry pooled sample | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |